Siplizumab for Sickle Cell Disease Transplant | MicrobiomeTrials← Back to trialsNCT06078696
Siplizumab for Sickle Cell Disease Transplant
TERMINATEDPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2023-09-28Est. Completion: 2024-12-11
Enrollment target: 1 participants Locations- Columbia University Irving Medical Center, New York, New York, United States
Other microbiome trials you might be interested in
Sickling Disorder Due to Hemoglobin S
The purpose of this study is to find the smallest amount of the 131 I-apamistamab needed for preparing patients with sev…
New York, United StatesEst. completion Mar 12, 2030
Sickle Cell Disease (SCD)Invasive Bacterial Infections
Children with sickle cell disease are at high risk of invasive bacterial infections, which may lead to serious complicat…
Argenteuil, FranceEst. completion Jul 15, 2027
Completed
The purpose of this clinical trial is to evaluate the performance of the sickle cell disease (SCD) electronic diary in p…
Hollywood, United StatesCompleted Jun 24, 2024